Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
16 hedge funds and large institutions have $5.43M invested in Hepion Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 12 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
3% less capital invested
Capital invested by funds: $5.6M → $5.43M (-$173K)
38% less funds holding
Funds holding: 26 → 16 (-10)
83% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$1.9M |
| 2 |
Morgan Stanley
New York
|
+$233K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$84.7K |
| 4 |
BlackRock
New York
|
+$68.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$25.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$122K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$103K |
| 3 |
Bank of New York Mellon
New York
|
-$68.9K |
| 4 |
ML
McAdam LLC
Philadelphia,
Pennsylvania
|
-$48.3K |
| 5 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$47.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ML
26
McAdam LLC
Philadelphia,
Pennsylvania
| – | -$48.3K | -62 | Closed |
|
|
PAM
27
PVG Asset Management
Golden,
Colorado
| – | -$47.5K | -61 | Closed |
|
|
VF
28
Virtu Financial
New York
| – | -$42K | -54 | Closed |
|
29
Charles Schwab
San Francisco,
California
| – | -$24.5K | -32 | Closed |
|
30
Two Sigma Advisers
New York
| – | -$20.1K | -26 | Closed |
|
31
Cetera Investment Advisers
Schaumburg,
Illinois
| – | -$15.3K | -20 | Closed |
|
|
IGGA
32
Iron Gate Global Advisors
Nsl,
Utah
| – | -$10.3K | -13 | Closed |
|
|
AWA
33
Amplius Wealth Advisors
Blue Bell,
Pennsylvania
| – | -$7.76K | -10 | Closed |
|
34
Citadel Advisors
Miami,
Florida
| – | -$1.28K | -2 | Closed |
|
HEPA Hedge Fund Activity: Q2 2023 in Review
16 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2023, worth a combined $5.43M — down 3.1% from $5.6M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of HEPA and 2 opened new positions — a net loss of 10 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $1.9M. The largest seller was Envestnet Asset Management, exiting entirely with an estimated $122K sold.
- 16 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2023, down from 26 in Q1 2023.
- Funds reported $5.43M of Hepion Pharmaceuticals stock for Q2 2023, down 3.1% quarter-over-quarter.
- 2 funds opened new Hepion Pharmaceuticals positions in Q2 2023 and 12 closed out, a net change of -10 holders.
- The largest Hepion Pharmaceuticals buyer in Q2 2023 was Octagon Capital Advisors, an estimated $1.9M added.
- The largest Hepion Pharmaceuticals seller in Q2 2023 was Envestnet Asset Management, an estimated $122K sold.
Based on aggregated 13F filings for Q2 2023.